Piper Sandler raised the firm’s price target on Alnylam to $217 from $210 and keeps an Overweight rating on the shares. The firm is a buyer of Alnylam ahead of Phase III HELIOS-B data on AMVUTTRA in ATTR-CM in early 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam to hold a virtual research and development day
- Qualcomm downgraded, First Solar upgraded: Wall Street’s top analyst calls
- Alnylam initiated with an Equal Weight at Wells Fargo
- Alnylam initiated with neutral view at Wells Fargo
- Alnylam presents results from KARDIA-1 Phase 2 dose-ranging study of Zilebesiran